Untreated gout gradually shifts from an occasional painful flare into a chronic, destructive disease that can damage joints, kidneys, and the cardiovascular system. What often begins as a single swollen toe can, over years, leave crystal deposits embedded throughout the body and raise the risk of kidney failure, heart disease, and even early death. The quiet periods between flares are deceptive: inflammation persists even when the pain does not, and the longer uric acid levels stay elevated, the harder the damage becomes to reverse.
How Gout Progresses Without Treatment
Gout starts when uric acid in the blood crystallizes and settles into joints, triggering intense inflammation. The first flare usually resolves on its own within a week or two, and many people assume the problem is gone. It is not. Between flares, urate crystals remain in the tissue and systemic inflammation continues at a lower level, even when you feel fine.1PubMed. Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker Research tracking inflammatory markers over time has confirmed that elevated inflammatory activity in gout persists beyond clinically obvious flare episodes and is not always captured by checking uric acid levels alone.2PubMed. Systemic Immune-Inflammation Index is associated with flare-related and intercritical inflammatory activity in gout: a longitudinal real-world repeated-measures study
Over time, flares tend to come more often, last longer, and affect more joints. A large prospective study following over a thousand gout patients in primary care identified six distinct flare trajectories. Some patients had infrequent episodes throughout the study period, but others followed a “gradually worsening” path, and a small group experienced frequent, persistent flares that never really let up.3PubMed. Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care Without treatment to lower uric acid, the disease tends to escalate rather than burn itself out.
Tophi and Permanent Joint Destruction
The most visible consequence of long-standing untreated gout is the tophus, a chalky lump that forms when urate crystals accumulate into organized masses within tissues. These are not simple calcium deposits. Under a microscope, a tophus looks like a chronic granuloma: a dense collection of urate crystals surrounded by inflammatory immune cells and fibrous connective tissue.4PubMed. The gouty tophus: a review Tophi can form not only around joints in the hands, feet, and elbows but also in tendons, ligaments, cartilage, skin, and even internal organs.5PubMed Central. The anatomical pathology of gout: a systematic literature review
The damage goes well beyond a visible lump. Urate crystals actively eat into bone. They promote the formation of osteoclasts, the cells that break down bone tissue, through direct interactions with surrounding cells. Crystals also kill cartilage cells, compromising the protective layer over bone surfaces and allowing the crystals to reach deeper structures.6PubMed Central. Urate crystal deposition and bone erosion in gout: ‘inside-out’ or ‘outside-in’? A dual-energy computed tomography study The net effect is bone erosion driven by oxidative stress, amplified inflammatory cascades, and disrupted bone remodeling.7PubMed Central. Mechanisms of monosodium urate crystal-induced bone destruction in gouty arthritis In advanced cases, the erosion can leave permanent holes in bone that are visible on X-rays, and joints may become deformed or functionally useless.
Kidney Damage and Kidney Stones
The kidneys handle most of the body’s uric acid excretion, so they take a heavy hit when urate levels stay chronically elevated. A meta-analysis pooling results from multiple observational studies found that roughly one in four people with gout already had chronic kidney disease at stage 3 or higher, and about one in seven reported a history of kidney stones.8PubMed Central. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies Compared to people without gout, those with the disease had more than double the odds of chronic kidney disease and nearly twice the odds of kidney stones in that same analysis.
A population-based cohort study put numbers on the trajectory: gout patients developed stage 3 or worse chronic kidney disease at nearly twice the rate of matched controls, with an adjusted hazard ratio of about 1.78.9PubMed Central. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study The relationship between gout and kidney stones appears to be causal, not just a shared risk factor. A study combining large survey data with genetic analysis found that gout raised the odds of developing kidney stones by about 45 percent, and the genetic evidence supported a direct causal link.10PubMed Central. Association between gout and kidney stone: results from mendelian randomization and the NHANES study
The type of stone matters too. High urinary uric acid drives the formation of uric acid stones specifically, and the key culprit is excessively acidic urine rather than the concentration of uric acid alone.11PubMed. Update on Uric Acid and the Kidney People with gout frequently have more acidic urine than average, creating an ideal environment for stone formation even if their kidney function is otherwise holding up.
Cardiovascular Risks
Gout increases the risk of heart disease, stroke, and other cardiovascular events. A systematic review and meta-analysis of sixteen studies comparing gout patients to matched controls found elevated risk across all categories of cardiovascular disease.12PubMed Central. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis The effect is not trivial. In a large cohort of men tracked over many years, those with gout had roughly a 38 percent higher risk of dying from cardiovascular causes and a 55 percent higher risk of fatal coronary heart disease, even after accounting for other risk factors.13PubMed. Independent impact of gout on mortality and risk for coronary heart disease
One plausible mechanism is that uric acid directly impairs blood vessel function. Lab and clinical research has shown that elevated serum uric acid is associated with endothelial dysfunction, the inability of blood vessels to dilate properly. In cell studies, uric acid reduced the activity of the enzyme that produces nitric oxide, the molecule that keeps vessels relaxed, particularly under low-oxygen conditions.14PubMed. Effects of uric acid on vascular endothelial function from bedside to bench Whether lowering uric acid directly fixes this vascular problem is less clear. A randomized trial testing whether urate-lowering drugs improved endothelial function did not support a straightforward causal link between uric acid levels and endothelial health.15PubMed Central. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial The relationship between gout and heart disease is real, but the mechanisms are still being untangled.
The Metabolic Tangle
Gout rarely shows up alone. People with the disease are far more likely to also have high blood pressure, type 2 diabetes, obesity, and high cholesterol. For years, researchers debated which condition drives which. A genetic analysis designed to tease apart cause and effect found that the arrow points in one direction for at least one major link: insulin resistance leads to higher uric acid, not the other way around.16PubMed Central. Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization In practical terms, this means that managing gout often requires addressing insulin resistance and metabolic syndrome at the same time, not just lowering uric acid in isolation.
This clustering of conditions is relevant to untreated gout because the metabolic problems compound one another. Chronic inflammation from gout worsens cardiovascular risk. Kidney damage from gout raises blood pressure. Insulin resistance makes the kidneys less efficient at excreting uric acid, which feeds back into more crystal deposition. Ignoring gout does not just leave one disease untreated; it leaves a whole web of interconnected conditions free to escalate together.
Crystal Deposits Start Before Symptoms Do
One unsettling finding from imaging research is that urate crystals can already be deposited in joints and tendons in people who have elevated uric acid but have never had a gout flare. A dual-energy CT study found crystal deposits in about a quarter of people with asymptomatic high uric acid, compared to roughly 80 percent of those with established gout.17PubMed. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study The volume of crystals in asymptomatic individuals was much lower, suggesting that a threshold amount of crystal buildup is needed before the body triggers an inflammatory flare. But the takeaway is that damage begins silently, well before the first attack of pain, and the longer you wait after that first attack, the more crystal has already accumulated.18PubMed Central. Dual‐energy CT in gout – A review of current concepts and applications
Mortality and Gout
The question of whether gout itself shortens life is complicated by the metabolic conditions that travel alongside it. A large Swedish cohort study found that gout increased all-cause mortality by about 24 percent in a basic model, but once researchers adjusted for conditions like diabetes, kidney disease, and cardiovascular disease, the excess risk largely disappeared for men and shrank to about 10 percent for women.19PubMed Central. Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study Cardiovascular death, however, remained significantly higher in gout patients of both sexes even in the fully adjusted model. Death from kidney disease was significantly elevated in men, and death from digestive system diseases was significantly elevated in women.
One surprising finding from that same study: death from dementia was significantly lower in gout patients, roughly 35 percent less, for both men and women.19PubMed Central. Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study This aligns with a long-standing hypothesis that uric acid has antioxidant properties that may protect the brain, though the reasons are still debated and no one is recommending gout as a dementia prevention strategy.
Quality of Life and Disability
Beyond organ damage, untreated gout erodes daily functioning in ways that clinical markers do not capture. In one study, patients with severe treatment-failure gout scored physical functioning levels comparable to those of the general population aged 75 and older, regardless of their actual age.20The Journal of Rheumatology. Quality of Life and Disability in Patients with Treatment-Failure Gout The number of flares, the number of swollen or tender joints, and the presence of tophi all correlated with worse quality of life across multiple measures.
An Italian observational study found that specific gout features independently worsened function even after accounting for other health conditions. Having tophi nearly doubled the odds of significant functional impairment, and polyarticular involvement nearly quadrupled them.21PubMed Central. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR) The physical decline was concentrated in patients whose gout had progressed to a chronic phase, reinforcing that early treatment matters. Additional research has linked disease duration, flare frequency, and the burden of tophi to higher rates of depression and anxiety among gout patients.22PubMed Central. Associated factors with functional disability and health-related quality of life in Chinese patients with gout: a case-control study
Depression and Anxiety
The psychological toll of gout is an underappreciated complication. A population-based cohort study found that people diagnosed with gout had a modestly but significantly elevated risk of developing depression and anxiety compared to matched controls without gout.23PubMed Central. Onset of depression and anxiety among patients with gout after diagnosis: a population-based incident cohort study A systematic review identified the number of tophi, the frequency of flares, and whether gout involved multiple joints as significant drivers of depression.24The Journal of Rheumatology. Epidemiology of Depression and Anxiety in Gout: A Systematic Review and Metaanalysis In other words, the features that mark untreated, advancing gout are the same features most strongly linked to mental health problems. Chronic pain, unpredictable flares, and visible joint deformity all feed anxiety, social withdrawal, and low mood.
What Treatment Can Reverse
The encouraging counterpoint to all of this is that much of the damage is reversible if uric acid is brought down far enough. Urate-lowering therapy does not just prevent future flares; it can actually dissolve existing crystal deposits. A five-year follow-up of gout patients treated to a target uric acid level found that uric acid dropped substantially from baseline, crystal deposits visible on ultrasound shrank dramatically, the visible “double contour” sign on joint surfaces dissolved in over 80 percent of patients, and tophi dissolved in about 63 percent. By year five, only 16 percent of patients were still experiencing flares.25PubMed. Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study Earlier work had established the same principle: lowering serum urate promotes shrinkage and eventual disappearance of tophi.26PubMed. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout
The catch is that the longer gout goes untreated, the more crystal has accumulated, the more bone erosion has occurred, and the harder it becomes to fully undo the structural damage. Dissolved crystals do not regrow destroyed bone. Treatment works best when it starts before the disease crosses from recurrent flares into established tophaceous gout with joint erosion.
Skin Ulceration Over Tophi
Large tophi, especially over bony prominences like the elbows, fingers, and toes, can erode through the skin and create open wounds. These ulcers are painful, slow to heal, and prone to secondary infection.27PubMed Central. Risk factors for ulceration over tophi in patients with gout The chalky white urate material sometimes drains through the wound, and the combination of an open wound and a compromised immune environment around the tophus makes management difficult. For people with untreated tophaceous gout, infection risk from ulcerated tophi is a concrete, practical threat that goes well beyond joint pain.
Unusual Places Gout Can Appear
Most people think of gout as a big-toe disease, and the first metatarsophalangeal joint is indeed the classic location. But urate crystals are not picky about where they settle. In rare cases, tophi form along the spine, where they can compress the spinal cord or nerve roots. A review of 68 reported spinal gout cases found that about 70 percent of patients had localized back or neck pain, and over half had some form of spinal cord compression causing weakness, numbness, or loss of bladder and bowel control.28PubMed Central. Spinal gout: A review with case illustration Because spinal gout is so uncommon, it is frequently misdiagnosed as a tumor or infection, delaying correct treatment. Case reports document patients who underwent surgery for what surgeons expected to be a tumor, only to find a chalky white gouty tophus compressing the spinal cord.29Korean Journal of Spine. Tophaceous Gout of the Spine Causing Neural Compression
Urate crystals have also been found in the eyes. A study examining gout patients for ocular abnormalities reported finding uric acid crystal deposits in the cornea and sclera of a small number of patients.30PubMed Central. Characteristics of ocular abnormalities in gout patients These are rare findings, but they illustrate how widespread crystal deposition can become when the disease runs unchecked for years. The eyes, the spine, the kidneys, tendons, and visceral organs are all potential landing sites.
Why Humans Are Especially Vulnerable to Gout
Most mammals never get gout because they produce an enzyme called uricase that breaks down uric acid into a more soluble compound the kidneys can easily flush. Humans lost the gene for this enzyme millions of years ago due to a mutation during primate evolution.31PubMed. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity As a result, human blood uric acid levels are far higher than those of most other mammals, sitting much closer to the threshold where crystals begin to form. Evolutionary research has shown that this loss of uricase occurred alongside changes in the kidney transporter that reabsorbs uric acid, suggesting the two events were linked and may have provided some survival advantage, perhaps related to maintaining blood pressure during periods of dietary scarcity.32PubMed Central. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
The practical upshot is that humans walk around with uric acid levels that are already close to the crystallization point. It does not take much, whether from diet, genetics, kidney function, or medication side effects, to tip the balance. This evolutionary quirk is why gout has plagued humans for millennia and why ignoring it is a particularly bad idea: your body has no built-in safety valve for excess uric acid the way most other species do.